Skip to content
Taxonomy
Data Shows Benefit with PXT3003 in Patients with CMT1A
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit Read More
Orphan Drug Designation for TSHA-120 for Treatment of GAN
Taysha Gene Therapies Receives Orphan Drug Designation from the European Read More
The CMTA Earns a Perfect Rating From Charity Navigator
The Charcot-Marie-Tooth Association Earns a Perfect Rating From Charity Navigator Read More
Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of Read More
CMTA Seed Money Draws NIH Support For Type 2 Gene Editing
CMTA Seed Money Draws NIH Support For Type 2 Gene Read More
CMTA-STAR Awards $354,826 for CMT Clinical Trial
CMTA-STAR Awards $354,826 for CMT Clinical Trial (Glenolden, PA, December Read More
CMTA-STAR Awards Researcher $98,985 For CMT1A Project
CMTA-STAR Awards Researcher $98,985 For CMT1A Project Using Dental Pulp Read More
CMTA and Taysha Gene Therapies Announce Collaboration for CMT4A
CMTA and Taysha Gene Therapies Announce Collaboration for CMT4A (Glenolden, Read More
CMTA and Applied Therapeutics Announce Collaboration for CMT-SORD
CMTA and Applied Therapeutics Announce Collaboration for CMT-SORD (Glenolden, PA, Read More
Taysha Gene Therapies & CMTA Collaborate to Increase Genetic Testing Access for Giant Axonal Neuropathy (GAN)
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Read More
